Archives
Closing of a transaction with funds managed by Goldman Sachs Asset Management
Signing of a transaction with funds managed by Goldman Sachs Asset Management
Enzymotec Ltd. reports third quarter 2015 results
Earns non-GAAP $0.08 and GAAP $0.07 per diluted share and generates $4.7 million in operating cash flow
VAYA Pharma generates record net revenues of $2.2 million
VR Equitypartner and BIP Investment Partners acquire LEUNA-Tenside
VR Equitypartner und BIP Investment Partners erwerben LEUNA-Tenside
Enzymotec reports second quarter 2015 results
Revenues and adjusted EBITDA increased for fourth consecutive quarter
Q2 net revenues increased 49.5% year-over-year